SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • January 19th, 2021 • Titan Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of January 15, 2021, between Titan Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
COMMON STOCK PURCHASE WARRANT Titan Pharmaceuticals, Inc.Common Stock Purchase Agreement • January 19th, 2021 • Titan Pharmaceuticals Inc • Biological products, (no disgnostic substances)
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on July ___, 2026[1] (the “Termination Date”) but not thereafter, to subscribe for and purchase from Titan Pharmaceuticals, Inc., a Delaware corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
Marc Rubin, M.D. Executive Chairman Titan Pharmaceuticals, Inc.Placement Agent Agreement • January 19th, 2021 • Titan Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York
